Showing results (301-310 of 324) with videos related to
Sort By:
Pageof 33
Cell Metabolism|April 10, 2018
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell TherapyTina Cascone, Jodi A McKenzie, Rina M Mbofung, et al.Cancer Discovery|April 21, 2026
Intratumoral sotigalimab with pembrolizumab induces rapid activation of antigen presenting cells and drives anti-tumor responses in non-injected tumors in metastatic melanoma: A phase I/II studySalah-Eddine Bentebibel, Daniel J McGrail, Veena Kochat, et al.Cancer Discovery|February 22, 2019
Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain MetastasesGrant M Fischer, Ali Jalali, David A Kircher, et al.The Lancet. Oncology|January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trialRodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.Cancer Immunology Research|May 12, 2023
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic CancerApostolia M Tsimberidou, Kerstin Guenther, Borje S Andersson, et al.The Journal of Investigative Dermatology|August 23, 2014
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanomaAlan E Siroy, Genevieve M Boland, Denái R Milton, et al.Nature Medicine|October 10, 2018
Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.Nature Medicine|October 27, 2018
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.Nature Medicine|October 27, 2018
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.Science Translational Medicine|March 3, 2017
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistanceWhijae Roh, Pei-Ling Chen, Alexandre Reuben, et al.Pageof 33